Lilly bolts on cancer bispecifics with $1.6bn Merus allianceAlways a big player in oncology, Eli Lilly has fallen behind some of its rivals when it comes Share XLilly bolts on cancer bispecifics with $1.6bn Merus alliancehttps://pharmaphorum.com/news/lilly-bolts-on-cancer-bispecifics-with-1-6bn-merus-alliance/
Celltrion closes in on COVID-19 antibody market after trial successSouth Korea’s Celltrion has announced encouraging top-line results for its potential antibody therapy for COVID-19, with the first Share XCelltrion closes in on COVID-19 antibody market after trial successhttps://pharmaphorum.com/news/celltrion-closes-in-on-covid-19-antibody-market-after-trial-success/
Could Lilly’s donanemab readout in Alzheimer’s boost Biogen’s prospects?When Eli Lilly reported results for donanemab in Alzheimer’s disease earlier this week it was hailed as a Share XCould Lilly’s donanemab readout in Alzheimer’s boost Biogen’s prospects?https://pharmaphorum.com/news/could-lillys-alzheimers-drug-readout-boost-biogens-prospects/
Boehringer, Lilly’s Jardiance ties to match AZ’s Farxiga with heart failure labelBoehringer and Eli Lilly have moved closer to a heart failure indication for their SGLT2 inhibitor Jardiance, as Share XBoehringer, Lilly’s Jardiance ties to match AZ’s Farxiga with heart failure labelhttps://pharmaphorum.com/news/boehringer-lillys-jardiance-ties-to-match-azs-farxiga-with-heart-failure-label/
Lilly pays up to $1.04bn for neurology gene therapy biotech PrevailEli Lilly has acquired Prevail, a biotech focusing on gene therapies for neurodegenerative diseases including Parkinson’s, in a Share XLilly pays up to $1.04bn for neurology gene therapy biotech Prevailhttps://pharmaphorum.com/news/lilly-buys-neurology-gene-therapy-biotech-prevail/
Lilly surges on positive phase 3 readout from diabetes contenderEli Lilly’s decision to throw large amounts of research dollars at its next-generation diabetes drug tirzepatide could be Share XLilly surges on positive phase 3 readout from diabetes contenderhttps://pharmaphorum.com/news/lilly-surges-on-positive-phase-3-readout-from-diabetes-contender/
ASH: Lilly builds case for its BTK drug LOXO-305 in lymphomaEli Lilly’s buyout of Loxo Oncology last year has already yielded one approved drug, and it now has Share XASH: Lilly builds case for its BTK drug LOXO-305 in lymphomahttps://pharmaphorum.com/news/ash-lilly-builds-case-for-its-btk-drug-loxo-305-in-lymphoma/
Lilly’s baricitinib granted US emergency use in COVID-19Doctors in the US are to get another option to treat COVID-19 after the FDA granted an Emergency Share XLilly’s baricitinib granted US emergency use in COVID-19https://pharmaphorum.com/news/lillys-baricitinib-granted-us-emergency-use-in-covid-19/
NICE backs Lilly’s Emgality for migraine, adding pressure on NovartisUK cost-effectiveness agency NICE has said that Eli Lilly’s Emgality can be made available through the NHS for Share XNICE backs Lilly’s Emgality for migraine, adding pressure on Novartishttps://pharmaphorum.com/news/nice-backs-lillys-emgality-for-migraine-adding-pressure-on-novartis-rival/